Novo Nordisk’s FREHEMGO Approved in EU for Haemophilia A
The European Commission granted marketing authorisation for FREHEMGO, with monthly, every-two-weeks or weekly dosing options.
The European Commission granted marketing authorisation for FREHEMGO, with monthly, every-two-weeks or weekly dosing options.